Dr Hiotis is a Surgical Oncologist at the Mount Sinai School of Medicine. He received his MD degree from the University of Maryland, and also holds a PhD in Immunology. Dr Hiotis trained in General Surgery at the University of South Florida in Tampa, and in Surgical Oncology at the Memorial Sloan-Kettering Cancer Center in New York. He has a strong interest in cancers of the liver and gastrointestinal tract. In addition to clinical practice in surgical oncology, Dr Hiotis is currently actively engaged in both clinical and laboratory research.
He is currently the principal investigator of an independently funded scientific research project, which focuses on the interaction between hepatic fibrosis and hepatocellular carcinoma in patients with hepatitis B. This project involves both a retrospective and prospective component. The prospective arm includes a tumor banking protocol, from which over 100 human tumor and non-neoplastic liver parenchymal specimens have already been collected and cryopreserved. This is a highly unique tumor bank, and only includes hepatocellular cancers from patients with hepatitis B. A broad spectrum of tumors have already been collected from patients with varying degrees of underlying hepatic fibrosis, which is a unique characteristic seen in patients with hepatitis B associated hepatocellular carcinoma. Dr Hiotis’ hepatitis B-hepatocellular carcinoma research project is designed to evaluate differences in hepatocellular carcinoma that arise in patients with underlying cirrhosis, vs. those cancers that arise instead in livers with minimal or moderate fibrosis. His additional research activities also include participation in clinical trials for treatment of liver and gastrointestinal cancers, and basic science research focusing on cancer immunotherapy in a mouse model for hepatocellular carcinoma.
American Board of Surgery
MD, University of Maryland
PhD, University of South Florida
Residency, Surgery (General)
University of South Florida
Fellowship, Surgical Oncology
Memorial Sloan-Kettering Cancer Center
Chinese (Cantonese), Chinese (Mandarin), English, Greek, Spanish
Dr. Hiotis is currently the Vice Chairman for Surgical Research at Mount Sinai. In this role, Dr. Hiotis administrates the coordinated clinical and basic science research efforts of a large department, including ten divisions and multiple full-time faculty members. He supervises the department’s research fellows, coordinators, and assistants.
In addition to his administrative responsibilities in research, Dr. Hiotis also maintains a research endeavor of his own, oversees a basic science laboratory, and is the principal investigator of independently-funded scientific research. He is also actively engaged in several clinical trials.
His recent open protocols include:
Roayaie S, Blume IN, Thung SN, Fiel MI, Hiotis SP, Labow DM, Llovet JM, Schwartz ME. Grading of Microscopic Vascular Invasion in Resected Hepatocellular Carcinoma. Gastroenterology 2009 September; 137(3): 850-855.
Marti JL, Hochster HS, Hiotis SP, Donohue B, Ryan T, Newman E. Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer. Annals of Surgical Oncology 2008 December; 15(12): 3521-3531.
Kim HJ, D'Angelica M, Hiotis SP, Shoup M, Weber SM. Laparoscopic Staging for Liver, Biliary, Pancreas, and Gastric Cancer. Current Problems in Surgery 2007 April; 44(4): 217-272.
Lim S, Muhs B, Marcus SM, Newman E, Burman RB, Hiotis SP. Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups? . Journal of Surgical Oncology 2007 February; 95(2): 118-122.
Newman E, Potmesil M, Ryan T, Marcus S, Hiotis S, Yee H, Norwood B, Wendell M, Muggia F, Hochster H. Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study. Seminars in Oncology 2005 December; 32(6): S97-100.
Klegar EK, Marcus SG, Newman E, Hiotis SP. Diagnostic Laparoscopy in the Evaluation of the Viral Hepatitis Patient with Potentially-Resectable Hepatocellular Carcinoma. HPB 2005 September; 7(3): 204-207.
Colen KL, Marcus SG, Newman E, Hiotis SP. Multiorgan Resection for Gastric Cancer: Intraoperative and Computed Tomography Assessment of Locally Advanced Disease is Inaccurate. Journal of Gastrointestinal Surgery 2004 November ; 8(7): 899-902.
Marcus SG, Cohen D, Lin K, Wong K, Thompson S, Rothberger A, Potmesil M, Hiotis S, Newman E. Complications of Gastrectomy Following CPT-11-based Neoadjuvant Chemotherapy for Gastric Cancer. Journal of Gastrointestinal Surgery 2003 December; 7(8): 1015-1022.
Hiotis SP, Wadghiri YZ, Yee HT, Luan W, Burakoff SJ. Magnetic Resonance Imaging of a Murine Model for Hepatocellular Carcinoma. Hepatology (Abstract) 2003 October; 38(4): 409A.
Hiotis SP, Klimstra DS, Conlon KC, Brennan MF. Results After Pancreatic Resection for Metastatic Lesions. Annals of Surgical Oncology 2002 August; 9(7): 675-679.
Hiotis SP, Weber SM, Cohen AM, Minsky BD, Guillem JG, Paty PB, Wong WD. Assessing the Predictive Value of Clinical Response to Combined Modality Therapy for Rectal Cancer; a Prospective Evaluation of 488 Patients. Journal of the American College of Surgeons 2002 February; 194(2): 131-125.
Spanknebel K, Temple L, Hiotis S, Yeh A, Coit D. Randomized Clinical Trials in Melanoma. Surgical Oncology Clinics of North America 2002 January; 11(1): 23-52.
Kocab MA, Coppola D, Hiotis SP, Karl RC, Barthel JS. Captopril-Associated Cholestasis Complicating the Management of Pancreatic Cancer.. Surgical Endoscopy 2000 July; 14(7): 681.
Hiotis SP, Wnuk KL, Good RA. Successful Limb Transplantation Across a Multi-Minor Barrier Facilitated by Preceding Engraftment of T-cell-Purged Donor and Recipient Bone Marrow. Transplantation Proceedings 1999 Feb-Mar; 31(1-2): 692-693.
Hiotis SP, Wnuk KL, Blumenthals WA, Halaris SA, Good RA. Orthotopic HindlimbTransplantation in the Rat: a Technically Challenging but Useful Model for Solid Organ Engraftment.. Transplantation Proceedings 1999 May; 31(3): 1567-1568.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Hiotis did not report having any of the following types of financial relationships with industry during 2016 and/or 2017: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.